Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial

Abstract

President of MiraVista Diagnostics. D.C.V. receives clinical trial funding from CSL Behring Canada, Shire Canada, and Cidara and an honorarium from Novartis Canada. The rest of the authors declare that they have no relevant conflicts of interest.

Allergen Immunotherapy in Children User’s Guide

“…A causal association between exposure to the suspected allergen and allergic symptoms must be established before the planning and administration of a long‐term, demanding treatment such as AIT. The occurrence of symptoms within the pollen season is normally considered a sufficient condition to start AIT . However, the etiological diagnosis of seasonal AR is difficult in polysensitized patients living in geographic areas with overlapping pollination seasons .…”

“…However, the etiological diagnosis of seasonal AR is difficult in polysensitized patients living in geographic areas with overlapping pollination seasons . Nasal challenge tests or controlled exposure in a pollen chamber is thus useful to demonstrate that the contact with a pollen is able to trigger allergic symptoms . The implementation of these tests, though, is mostly limited to ENT specialists and few centers where they have to be performed under safe conditions.…”

“…Parallelly, production and documentation requirements have become significantly more complex . Albeit the conventional routes of administration remain subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), and oral immunotherapy (OIT), new approaches, such as epicutaneous and intralymphatic applications, are under investigation . Moreover, AIT has been used in a wide range of allergic disorders and their different constellations, such as allergic rhinitis, allergic conjunctivitis, and allergic asthma as well as food, venom, and drug allergies .…”

Recent developments and highlights in allergic rhinitis

“…95 Recently, the efficacy and notably low adverse effects of intralymphatic immunotherapy (ILIT) have been confirmed. 96 Modified allergens such as recombinant allergens, allergoids, and allergen peptides have also recently been developed for use in AIT.…”

Intralymphatic Immunotherapy: Update and Unmet Needs

“…One trial with 60 patients randomised 1: 1 to receive combined injections of birch and grass pollen allergen or placebo found the treatment to be safe and effective [22]. The sum of nasal symptoms was reduced by 25% at follow-up after 6–9 months in the verum group, whereas no reduction was observed in the placebo group.…”